期刊文献+

C反应蛋白和B型利钠肽与终末期肾病患者心力衰竭的关系

原文传递
导出
摘要 目的探讨终末期肾病(ESRD)患者C反应蛋白(CRP)和B型利钠肽(BNP)与心力衰竭的关系。方法研究对象为53例ESRD(CKD5期)患者,分成非心力衰竭组34例,心力衰竭组19例,非ESRD患者(CKD3期和CKD4期)组36例,健康体检者10例为对照组,同时检测其超敏CRP、BNP、血清尿素氮、肌酐、血清白蛋白(Alb)和血红蛋白(Hb)。行超声心动图检查测量左房内径(LAD)、舒张末期内径(LVEDD)、左室射血分数(LVEF)。结果ESRD(CKD5期)中心力衰竭组CRP、BNP与非心力衰竭组、非ESRD患者(CKD3期、CKD4期)组比较,差异有统计学意义(P〈0.01)。心力衰竭组LAD、LVEDD、LVEF与非心力衰竭组比较,差异有统计学意义(P〈0.01)。BNP水平与肌酐清除率(Ccr)、Alb、Hb呈负相关,BNP水平与CRP呈正相关(P〈0.01)。结论CRP浓度可作为判断心力衰竭的病情程度,BNP能敏感特异性地反映心室功能紊乱程度,对于ESRD患者,当CRP〉10mg/L,BNP水平〉100ng/L时,要预防心血管并发症的发生,改善患者的低蛋白血症和贫血状况,当BNP水平〉500ng/L,要及早对患者进行血液透析或腹膜透析治疗。
出处 《中国医师杂志》 CAS 2009年第1期109-110,共2页 Journal of Chinese Physician
  • 相关文献

参考文献6

  • 1Dokainish H, Zoghbi WA, Lakkis NM, et al. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the dianosis of congestive heart failure. Am J Cardio1,20(M ,93 (9) :1130- 1135,
  • 2牛杏果,赵玉兰.慢性心力衰竭心肌重塑机制及干预治疗[J].心血管病学进展,2005,26(3):281-284. 被引量:20
  • 3Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure. Int J Cardiol, 2004,95 ( 1 ) :49-54.
  • 4Garibotto G, Sofia A, Procopio V,et al. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of endstage renal disease and microinflammatory state. Kidney Int,2006,70 (2) :384-390.
  • 5Coppola A, De Paola G, Suppa M, et al. Therapy optimization of heart failure through the evaluation of the plasma concentration variation of B-type natriuretic peptide. Clin Ter,2006,157:495-505.
  • 6Mccullough PA, Duc P, Omland T,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: Ananalysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis,2003,4 (3) :571-579.

二级参考文献25

  • 1Colucci WS.Molecular and cellular mechanisms of myocardial failure[J].Am J Cardiol,1997,80:15L-25L.
  • 2Briest W,Holzl A,Rassler B,et al.Cardiac remodeling after long term norepinephrine treatment in rats[J].Cardiovasc Res,2001,52(2):265-273.
  • 3Lijnen PJ,Petrov VV,Fagard RH.Induction of cardiac fibrosis by angiotensin-Ⅱ[J].Methods Find Exp Clin Pharmacol,2000,22(10):709-723.
  • 4Kawano H,Do YS,Kawano Y,et al.Angiotensin Ⅱhas multiple profibrotic effects in human cardiac fibroblasts[J].Circulation,2000,101(10):1130-1137.
  • 5Lijnen P,Petrov V.Induction of cardiac fibrosis by aldosterone[J].Mol Cell Cardiol,2000,32(6):865-879.
  • 6Zannad F,Alla F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study(RALES).(Rales Investigators)[J].Circulation,2000,102(22):2700-2706.
  • 7Wang D,Liu YH,Yang XP,et al.Role of a selective aldosterone blocker in mice with chronic heart failure [J].Card Fail,2004,10(1):67-73.
  • 8Spninale FG,Coker ML,Heung LJ,et al.A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure[J].Circulation,2000,102:1944-1949.
  • 9Peterson JT.Matrix metalloproteinase inhibitor development and the remodeling of drug discovery[J].Heart Fail Rev,2004,9(1):63-79.
  • 10Shioi T,Matsumori A,Kihara Y,et al.Increased expression of interleukin-1β and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload[J].Circ Res,1997,81(5):664-671.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部